Status:
COMPLETED
Precedex Special Investigation (in Pediatric Patients)
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Maruishi Pharmaceutical
Conditions:
Sedation
Eligibility:
All Genders
45-17 years
Brief Summary
Secondary Data Collection:To confirm the safety and effectiveness profiles under the actual medical practice of Precedex in Japan.
Detailed Description
To assess the data, including safety profile, of Precedex Intravenous Solution administered for "sedation during and after mechanical ventilation in the intensive care setting" in pediatric patients u...
Eligibility Criteria
Inclusion
- Pediatric patients (45 weeks corrected gestational age to \<18 years old) administered this drug for "sedation during and after mechanical ventilation in the intensive care setting.
Exclusion
- No exclusion criteria is set out in this study.
Key Trial Info
Start Date :
July 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 8 2022
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT04040439
Start Date
July 30 2019
End Date
August 8 2022
Last Update
February 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Japan Local Country Office
Tokyo, Japan